Preclinically, inhibition of CSF1R using monoclonal antibodies (mAbs) or small molecule drugs, such as BLZ945 and PLX3397, have been used to treat malignancies including breast, ovarian, brain, pancreatic and other cancers where they decrease TAM accumulation and promote tumor growth inhibition (47, 82–84). This evidence concerns the gene CSF1R and cancer.